54 related articles for article (PubMed ID: 33416143)
1. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
[TBL] [Abstract][Full Text] [Related]
2. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract][Full Text] [Related]
3. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
[TBL] [Abstract][Full Text] [Related]
4. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
[TBL] [Abstract][Full Text] [Related]
5. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L
J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biological Evaluation of RGD and isoDGR-Monomethyl Auristatin Conjugates Targeting Integrin α
Raposo Moreira Dias A; Bodero L; Martins A; Arosio D; Gazzola S; Belvisi L; Pignataro L; Steinkühler C; Dal Corso A; Gennari C; Piarulli U
ChemMedChem; 2019 May; 14(9):938-942. PubMed ID: 30840356
[TBL] [Abstract][Full Text] [Related]
7. A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC).
Zhang J; Zhou ZZ; Chen K; Kim S; Cho IS; Varadkar T; Baker H; Cho JH; Zhou L; Liu XM
Cells; 2023 Sep; 12(19):. PubMed ID: 37830607
[TBL] [Abstract][Full Text] [Related]
8. A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.
Shi J; Jiao T; Guo Q; Weng W; Ma L; Zhang Q; Wang L; Zhang J; Chen C; Huang Y; Wang M; Pan R; Tang Y; Hu W; Meng T; Liu SH; Guo J; Kong Y; Meng X
Cancer Res; 2023 Nov; 83(22):3783-3795. PubMed ID: 37668527
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD44 Variant 5 with an Antibody-Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma.
Bei Y; He J; Dong X; Wang Y; Wang S; Guo W; Cai C; Xu Z; Wei J; Liu B; Zhang N; Shen P
Cancer Res; 2023 Jul; 83(14):2405-2420. PubMed ID: 37205633
[TBL] [Abstract][Full Text] [Related]
10. An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment.
Chang FL; Lee CC; Tsai KC; Lin TY; Chiang CW; Pan SL; Lee YC
Biochem Biophys Res Commun; 2023 Dec; 688():149214. PubMed ID: 37951154
[TBL] [Abstract][Full Text] [Related]
11. Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma.
Uchida S; Serada S; Suzuki Y; Funajima E; Kitakami K; Dobashi K; Tamatani S; Sato Y; Beppu T; Ogasawara K; Naka T
Neoplasia; 2024 Apr; 50():100982. PubMed ID: 38417223
[TBL] [Abstract][Full Text] [Related]
12. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.
Liu K; Li M; Li Y; Li Y; Chen Z; Tang Y; Yang M; Deng G; Liu H
Mol Cancer; 2024 Mar; 23(1):62. PubMed ID: 38519953
[TBL] [Abstract][Full Text] [Related]
13. CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma.
Parameswaran N; Luo L; Zhang L; Chen J; DiFilippo FP; Androjna C; Fox DA; Ondrejka SL; Hsi ED; Jagadeesh D; Lindner DJ; Lin F
Leukemia; 2023 Oct; 37(10):2050-2057. PubMed ID: 37573404
[TBL] [Abstract][Full Text] [Related]
14. Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy.
Si Y; Kim S; Ou J; Lu Y; Ernst P; Chen K; Whitt J; Carter AM; Markert JM; Bibb JA; Chen H; Zhou L; Jaskula-Sztul R; Liu XM
Cancer Gene Ther; 2021 Aug; 28(7-8):799-812. PubMed ID: 32684623
[TBL] [Abstract][Full Text] [Related]
15. Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation.
Hamilton JZ; Pires TA; Mitchell JA; Cochran JH; Emmerton KK; Zaval M; Stone IJ; Anderson ME; Jin S; Waight AB; Lyon RP; Senter PD; Jeffrey SC; Burke PJ
ChemMedChem; 2021 Apr; 16(7):1077-1081. PubMed ID: 33369163
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
[TBL] [Abstract][Full Text] [Related]
17. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.
Agarwal S; Fang L; McGowen K; Yin J; Bowman J; Ku AT; Alilin AN; Corey E; Roudier MP; True LD; Dumpit R; Coleman I; Lee JK; Nelson PS; Capaldo BJ; Mariani A; Hoover C; Senatorov IS; Beshiri M; Sowalsky AG; Hurt EM; Kelly K
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37725435
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of the PD0721‑DOX antibody‑drug conjugate targeting EGFRvIII to inhibit glioblastoma.
Hu M; Liu H; Zhang Y; Lu D; Zheng L; Wang Y; Chen S; Liu T
Exp Ther Med; 2024 Jun; 27(6):254. PubMed ID: 38682116
[TBL] [Abstract][Full Text] [Related]
19. Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates Losatuxizumab vedotin and Depatux-M in glioblastoma models.
Jain S; Griffith JI; Porath KA; Rathi S; Le J; Pasa TI; Decker PA; Gupta SK; Hu Z; Carlson BL; Bakken K; Burgenske DM; Feldsien TM; Lefebvre DR; Vaubel RA; Eckel-Passow JE; Reilly EB; Elmquist WF; Sarkaria JN
Clin Cancer Res; 2024 May; ():. PubMed ID: 38743766
[TBL] [Abstract][Full Text] [Related]
20. A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders.
Zhang L; Luo L; Chen JY; Singh R; Baldwin WM; Fox DA; Lindner DJ; Martin DF; Caspi RR; Lin F
JCI Insight; 2023 Dec; 8(23):. PubMed ID: 37917882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
